CompletedEUCTR 2008-007482-23
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression
This historical record does not confirm current site availability.
Historical research recordMultiple countriesBipolarity
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with bipolarity. Other eligibility criteria applied.
- Listed locations
- Czechia · France and 1 more location
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 340
- Sponsor
- Sunovion Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Czechia, Germany
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2008-007482-23
- Official title
Show the full official title
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedCzechia · France · Germany
Questions about this study
Who is behind this study?
The study sponsor is Sunovion Pharmaceuticals, Inc.
Who was this study for?
This study was for people with bipolarity. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...